Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep;7(9):999-1005.
doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.

Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors

David Quigley  1   2 , Joshi J Alumkal  3   4 , Alexander W Wyatt  5 , Vishal Kothari  1   6 , Adam Foye  1   7 , Paul Lloyd  1   7 , Rahul Aggarwal  1   7 , Won Kim  1   7 , Eric Lu  3 , Jacob Schwartzman  3 , Kevin Beja  5 , Matti Annala  5   8 , Rajdeep Das  1   6 , Morgan Diolaiti  1 , Colin Pritchard  9 , George Thomas  3   10 , Scott Tomlins  11 , Karen Knudsen  12 , Christopher J Lord  13 , Charles Ryan  1   7 , Jack Youngren  1   7 , Tomasz M Beer  3 , Alan Ashworth  14   15 , Eric J Small  14   7 , Felix Y Feng  14   6
Affiliations

Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors

David Quigley et al. Cancer Discov. 2017 Sep.

Abstract

Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib. In ovarian or breast cancers, olaparib resistance has been associated with HRR restoration, including by BRCA2 mutation reversion. Whether similar mechanisms operate in prostate cancer, and could be detected in liquid biopsies, is unclear. Here, we identify BRCA2 reversion mutations associated with olaparib and talazoparib resistance in patients with prostate cancer. Analysis of circulating cell-free DNA (cfDNA) reveals reversion mutation heterogeneity not discernable from a single solid-tumor biopsy and potentially allows monitoring for the emergence of PARPi resistance.Significance: The mechanisms of clinical resistance to PARPi in DNA repair-deficient prostate cancer have not been described. Here, we show BRCA2 reversion mutations in patients with prostate cancer with metastatic disease who developed resistance to talazoparib and olaparib. Furthermore, we show that PARPi resistance is highly multiclonal and that cfDNA allows monitoring for PARPi resistance. Cancer Discov; 7(9); 999-1005. ©2017 AACR.See related commentary by Domchek, p. 937See related article by Kondrashova et al., p. 984See related article by Goodall et al., p. 1006This article is highlighted in the In This Issue feature, p. 920.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

AA and CJL are named inventors on patents describing the use of PARP inhibitors and as such stand to gain financially as part of the ICR “Rewards to Inventors” Scheme.

Figures

Figure 1
Figure 1. PARPi resistance by multiple large deletions
1a: Timeline of patient 1’s serum PSA level before and during treatment with talazoparib. 1b: H&E stains of the solid tumor biopsy pre- and post-talazoparib were consistent with approximately 60% tumor purity. 1c: DNA read coverage of patient 1’s germline, pre- and post-talazoparib solid tumor, and post-talazoparib liquid biopsy. Horizontal white lines indicate the span of deletions, numbered D1 through D7, with deletion frequency indicated at the right side. The location and frequency of the p.K1872X/wild type allele is noted in gold/blue. 1d: Schematic protein models for BRCA2 WT, p.K1872X, and reversion isoforms. 1e: PCR amplification of the region around deletions D1 and D2 in patient 1’s germline, pre-talazoparib, and post-talazoparib solid biopsy confirms the presence of deletions D1 and D2 in post-talazoparib DNA.
Figure 2
Figure 2. Olaparib resistance in Patient 2 was associated with reversion mutations
2a: Timeline of patient 2’s serum PSA level before and during treatment with olaparib, showing a drop in PSA from 355 to a nadir of 40, followed by increase associated with drug resistance. 2b: CT scans from patient 2 pre-olaparib, on treatment, and after resistance show a liver metastasis at 17 mm on 2/8/16, decreased to 6 mm on 6/16/16 after olaparib treatment began, and at 18 mm on 9/13/16 respectively. 2c: Bone scans of patient 2 at times matching 2b, showing widespread metastasis, treatment response, and recurrence of metastatic lesions. 2d: Counts of indels observed exclusively in resistant cfDNA, binned into 50 bp intervals across BRCA2. Exon bounds shown at top. The pathogenic stop gain in p.R259fs allele is at nucleotide 1050, noted with red arrow. 2e: Diagram of BRCA2 reversion mutation alleles observed in patient 2. Wild type BRCA2 nucleotide and protein sequence, p.R259fs nucleotide and protein sequence, and BRCA2 reversion alleles present in patient 2’s post-olaparib DNA in all of exon 9 and the first 48 nucleotides of exon 10. Black vs. grey bars indicates observed vs. inferred nucleotide sequence. Deleted nucleotides shown as a thin black line with tics for each deleted nucleotide, insertions highlighted in blue, mutations highlighted in orange, alternate splice acceptor highlighted in green. For clarity, nucleotides are draw on reversion alleles where insertions are present; otherwise nucleotide sequence corresponds to WT. Count of each allele is shown at right.
See this image and copyright information in PMC

Comment in

Similar articles

  • Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
    Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS; TOPARP-A investigators. Goodall J, et al. Cancer Discov. 2017 Sep;7(9):1006-1017. doi: 10.1158/2159-8290.CD-17-0261. Epub 2017 Apr 27. Cancer Discov. 2017. PMID: 28450425 Free PMC article. Clinical Trial.
  • The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
    Herencia-Ropero A, Llop-Guevara A, Staniszewska AD, Domènech-Vivó J, García-Galea E, Moles-Fernández A, Pedretti F, Domènech H, Rodríguez O, Guzmán M, Arenas EJ, Verdaguer H, Calero-Nieto FJ, Talbot S, Tobalina L, Leo E, Lau A, Nuciforo P, Dienstmann R, Macarulla T, Arribas J, Díez O, Gutiérrez-Enríquez S, Forment JV, O'Connor MJ, Albertella M, Balmaña J, Serra V. Herencia-Ropero A, et al. Genome Med. 2024 Aug 26;16(1):107. doi: 10.1186/s13073-024-01370-z. Genome Med. 2024. PMID: 39187844 Free PMC article.
  • Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC. Weigelt B, et al. Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765325 Free PMC article.
  • Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Zimmer AS, et al. Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2. Curr Treat Options Oncol. 2018. PMID: 29644491 Free PMC article. Review.
  • Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG, Robson ME. Lyons TG, et al. J Natl Compr Canc Netw. 2018 Sep;16(9):1150-1156. doi: 10.6004/jnccn.2018.7031. J Natl Compr Canc Netw. 2018. PMID: 30181424 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310–1316. - PubMed
    1. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99:929–935. - PubMed
    1. Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748–1757. - PMC - PubMed
    1. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375:443–453. - PMC - PubMed
    1. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–1228. - PMC - PubMed

MeSH terms